The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy.
Our objective was to determine the effect of body mass index (BMI) on response to bacterial vaginosis (BV) treatment. A secondary analysis was conducted of two multicenter trials of therapy for BV and TRICHOMONAS VAGINALIS. Gravida were screened for BV between 8 and 22 weeks and randomized between 16 and 23 weeks to metronidazole or placebo. Of 1497 gravida with asymptomatic BV and preconceptional BMI, 738 were randomized to metronidazole; BMI was divided into categories: < 25, 25 to 29.9, and > or = 30. Rates of BV persistence at follow-up were compared using the Mantel-Haenszel chi square. Multiple logistic regression was used to evaluate the effect of BMI on BV persistence at follow-up, adjusting for potential confounders. No association was identified between BMI and BV rate at follow-up ( P = 0.21). BMI was associated with maternal age, smoking, marital status, and black race. Compared with women with BMI of < 25, adjusted odds ratio (OR) of BV at follow-up were BMI 25 to 29.9: OR, 0.66, 95% CI 0.43 to 1.02; BMI > or = 30: OR, 0.83, 95% CI 0.54 to 1.26. We concluded that the persistence of BV after treatment was not related to BMI.
Mastrobattista
Joan M
JM
Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, Texas 77030, USA.
Klebanoff
Mark A
MA
Carey
J Christopher
JC
Hauth
John C
JC
Macpherson
Cora A
CA
Ernest
J
J
Cotroneo
Margaret
M
Leveno
Kenneth J
KJ
Wapner
Ronald
R
Varner
Michael
M
Iams
Jay D
JD
Moawad
Atef
A
Sibai
Baha M
BM
Miodovnik
Menachem
M
Dombrowski
Mitchell
M
O'Sullivan
Mary J
MJ
Vandorsten
J Peter
JP
Langer
Oded
O
D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009767:Obesity, Morbid / Q000150:complications; D050177:Overweight / Q000150:complications; D011247:Pregnancy; D011248:Pregnancy Complications; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014247:Trichomonas Vaginitis / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D008795:Metronidazole